Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

Background: Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials. Methods: We conducted a search in PubMed, Web of Sci...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Psychiatry
Asıl Yazarlar: Morel, Alix, Lebard, Pierre, Dereux, Alexandra, Azuar, Julien, Questel, Frank, Bellivier, Frank, Marie-Claire, Cynthia, Fatséas, Mélina, Vorspan, Florence, Bloch, Vanessa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Psychiatry
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937926/
https://ncbi.nlm.nih.gov/pubmed/33692705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2021.565617
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller